QIAGEN Reports Strong Second Quarter 2009 Resul...

Corporate news announcement processed and transmitted by Hugin AS.
The issuer is solely responsible for the content of this 
announcement. 
----------------------------------------------------------------------
--------------    




  * 19% Revenue Growth on Constant Exchange Rates
  * 12% Organic Growth
  * $0.24 Adjusted EPS, exceeds guidance

Venlo, The Netherlands, August 10, 2009 - QIAGEN N.V. (Nasdaq: QGEN;
Frankfurt, Prime Standard: QIA) today announced the results of
operations for the second quarter and the six-month period ended June
30, 2009.

The reported net sales came in at  the high end of, and the  adjusted
earnings per share for the second quarter 2009 exceeded, the guidance
provided by the Company on May 5, 2009.

Second Quarter 2009 Results


QIAGEN's Second Quarter 2009 (in US$ millions, except per share
information)
                                           Q2 2009   Q2 2008   Growth

Net sales                                    240.2     217.9      10%
Net sales at constant exchange rates         258.2     217.9      19%
Operating income, adjusted                    71.8      60.6      19%
Net income, adjusted                          48.3      40.4      19%
EPS, adjusted (US$)                           0.24      0.20      20%


For  information  on  the  adjusted  figures,  please  refer  to  the
reconciliation table
accompanying this release.

The Company  reported  that consolidated  net  sales for  its  second
quarter 2009 increased 10% to  $240.2 million from $217.9 million  in
the same  quarter  in 2008.  Excluding  the unfavorable  impact  from
foreign currency exchange  rates, net  sales for  the second  quarter
2009 would have increased 19%. The reported operating income for  the
quarter increased 38% to $46.9 million from $34.0 million in the same
quarter of 2008,  and net  income for  the quarter  increased 33%  to
$30.9 million from $23.2 million in the same quarter of 2008. Diluted
earnings per share for the second  quarter increased 36% to $0.15  in
2009 from $0.11 in 2008.

On an adjusted basis, second  quarter operating income increased  19%
to $71.8  million in  2009 from  $60.6 million  in 2008,  and  second
quarter 2009 adjusted net income increased 19% to $48.3 million  from
$40.4 million in 2008. Adjusted diluted earnings per share  increased
20% to $0.24 in the second quarter 2009 from $0.20 in 2008.

Six-Month Period 2009 Results

For the six-month period ended June 30, 2009, net sales increased  8%
to $461.1 million compared to $425.0 million in the respective period
of 2008. Operating income as reported  for the six months ended  June
30, 2009 increased 25%  to $83.9 million from  $67.0 million for  the
same period in 2008. Net income  increased 28% to $55.6 million  from
$43.6 million in 2008, and  diluted earnings per share increased  29%
to $0.27 in 2009 from $0.21 in 2008.

On an adjusted basis, operating income for the six-month period ended
June 30, 2009  increased 10% to  $130.9 million in  2009 from  $119.4
million in  2008, and  adjusted  net income  increased 14%  to  $88.5
million from $77.4  million. Adjusted diluted  earnings per share  in
the six months ended June 30,  2009 increased 16% to $0.44 per  share
from $0.38 per share in the same period of 2008.

QIAGEN's second  quarter  and first  half  2009 results  include  the
results of  operations from  the Company's  recent acquisitions,  the
most significant of which was Corbett Life Science, acquired in  July
2008. Reconciliations of  reported results  determined in  accordance
with generally  accepted  accounting principles  (GAAP)  to  adjusted
results are included in the tables accompanying this release.

"We are very  pleased with  our financial performance  in the  second
quarter of 2009," said Peer Schatz, QIAGEN's Chief Executive Officer.
"We saw strong revenue and adjusted net income growth. The markets we
serve demonstrated  robust  demand  and solid  economic  trends.  Our
growth opportunities  are very  significant -  in particular  in  the
molecular diagnostics and applied testing markets - and we feel  well
positioned and  equipped to  convert these  trends and  opportunities
into significant value for QIAGEN and our shareholders."

 "We experienced  strong  revenue growth  for  QIAGEN in  the  second
quarter of 2009 and maintain  a positive outlook. Growth was  highest
in sales to customers in molecular diagnostics (approximately 48%  of
total revenues) followed by sales to customers in applied testing, in
academia and pharma ."

"Growth of our sales to customers in molecular diagnostics was fueled
by strong growth in sales of our screening products (primarily  HPV),
personalized  medicine  diagnostics   (including  our  KRAS   testing
solutions) and infectious disease tests (including our solutions  for
the surveillance of  H1N1 infections).  The development  of our  Next
Generation high throughput screening  system with the related  assays
is well on track  with clinical trials expected  to start in  several
weeks. We are also very excited about the future growth opportunities
especially in companion diagnostics  after recent recommendations  by
regulatory agencies  and  are  experiencing a  significant  level  of
activity in this  area of  our business.  Sales to  customers in  the
pharmaceutical and biotech  industry conducting clinical  development
continued to experience strong growth and sales to such customers for
discovery purposes (under 10% of our sales) were, as expected,  soft.
We are very  optimistic about  the potential growth  in the  academic
research markets following the American Recovery and Reinvestment Act
(ARRA) and other international stimulus  programs as well as  further
governmental long-term funding increase commitments. QIAGEN is active
in numerous initiatives to support its customers to benefit from both
the short-term  stimulus  programs  and from  the  planned  long-term
funding increases."

 "QIAGEN experienced a successful  second quarter. Reported  revenues
came in at the high end of, and adjusted earnings per share  exceeded
our expectations,"  said  Roland Sackers,  QIAGEN's  Chief  Financial
Officer. "Assuming constant exchange rates for both quarters  revenue
growth would have been 19% and was fueled by a strong organic  growth
of 12%  and a  positive  contribution of  6% from  acquisitions.  Our
consumable portfolio contributed 5% growth (12% at constant  exchange
rates). In  the  wake  of  new product  introductions  (such  as  the
QIAsymphony, the QIAgility, the EZ1 Advanced XL and the Rotor-Gene Q)
beginning this  year,  QIAGEN's  sales  of  instrumentation  products
recorded a growth rate of 66%  (83% at constant exchange rates).  Net
sales in  the  Americas  for  the  second  quarter  2009  represented
approximately 50% of our overall business and recorded a growth  rate
of 14% at constant exchange rates and European sales, which represent
approximately 35% of our  revenues, showed a  similar growth rate  of
14% at constant exchange  rates. Net sales  in Asia remained  strong,
showing a growth rate of 43% at constant exchange rates."

Increase of Fiscal Year 2009 Guidance Range

Based on the successful  first six months  and an optimistic  outlook
for the rest of the year, QIAGEN is hereby increasing its revenue and
EPS guidance for the fiscal year 2009. Revenue guidance is  increased
from the  previous range  from $920  million to  $970 million  (which
included approximately $10 million of revenues related to the  Olerup
product line sold end of June  2009) to now between $930 million  and
$970 million  post-divestment  of the  Olerup  product line  for  the
fiscal year 2009. Under constant exchange rates, revenue expectations
for 2009 would show growth rates between 11% and 16% when compared to
2008. QIAGEN  also increased  its expectations  for adjusted  diluted
earnings per share from the previous  range of $0.88 to $0.94 to  now
between $0.90 and $0.94. As always,  the revenue and EPS guidance  is
based on foreign currency exchange rates as of January 31, 2009.

QIAGEN - Sample and Assay Technologies Highlights


  * In August 2009, QIAGEN acquired Explera s.r.l., a leading
    supplier in molecular diagnostics and personalized medicine in
    Italy. With this acquisition QIAGEN is doubling the size of its
    molecular diagnostics sales channel in Italy and is adding
    several activities in the area of personalized medicine and
    access to a suite of CE-IVD pyrosequencing assays. QIAGEN expects
    this transaction to contribute approximately $1 million in sales
    for the remainder of fiscal year 2009 and approx. $5 million for
    the full year of 2010.

  * In July 2009, QIAGEN signed an agreement to transfer all
    distribution rights for the Olerup SSP® product line and the
    related assets to Olerup International AB, a subsidiary of
    LinkMed, a Swedish venture capital company. The Olerup SSP®
    product line includes molecular transplantation testing products
    used for DNA HLA typing. QIAGEN will retain rights to all Olerup
    SSP® assays for applications outside transplantation testing,
    such as in personalized medicine. This divesture allows QIAGEN to
    increase its focus on the higher growth applications in
    transplantation testing such as sequencing-based typing, as well
    as the application of such assays in personalized medicine.

  * In May 2009, QIAGEN entered into an agreement to supply molecular
    sample and assay technologies for a new national, PCR-based blood
    screening program for HIV and Hepatitis C (HCV) in Brazil. QIAGEN
    will provide Bio-Manguinhos, the main provider of vaccines and
    diagnostics to the Brazilian Ministry of Health, with a
    significant volume of molecular testing solutions - sample and
    assay technologies, related instrumentation, operational know-how
    and training. The agreement is expected to run for five years and
    contains options for subsequent extensions.

  * In the first half of 2009, QIAGEN launched more than 39 new
    products in the area of Sample & Assay Technologies including a
    novel PAXgene Blood miRNA kit for use in cancer, biomarker and
    miRNA research and the QIAamp Circulating Nucleic Acid kit for
    sample preparation in prenatal or other circulating nucleic acid
    research. In addition QIAGEN launched a number of assay
    technologies including a next generation CE marked mutation
    profiling KRAS test as well as a BRAF test for use in cancer
    treatments and a test for epigenetic methylation analysis based
    on pyrosequencing technology. Further new products included a
    suite of fast multiplex real-time PCR kits for gene expression
    analysis and siRNA validation.


Conference Call and Webcast Details

Detailed information on QIAGEN's  business and financial  performance
will be presented during  its conference call on  August 11, 2009  at
9:30am ET. The  corresponding presentation slides  will be  available
for     download      on      the      Company's      website      at
www.qiagen.com/goto/ConferenceCall. A webcast of the conference  call
will also be available at www.qiagen.com/goto/ConferenceCall.

Use of Adjusted Results

QIAGEN has  regularly reported  adjusted results  to give  additional
insight into its financial performance as well as considered  results
on a constant currencies basis. Adjusted results should be considered
in addition  to  the reported  results  prepared in  accordance  with
generally  accepted  accounting   principles,  but   should  not   be
considered as a substitute. The Company believes certain items should
be excluded  from  adjusted results  when  they are  outside  of  its
ongoing core operations, vary significantly from period to period, or
affect the comparability  of results with  the Company's  competitors
and its own  prior periods.  Reconciliations of  reported results  to
adjusted  results  are  included  in  the  tables  accompanying  this
release.

About QIAGEN

QIAGEN N.V., a  Netherlands holding  company, is  the leading  global
provider of sample  and assay technologies.  Sample technologies  are
used to isolate  and process  DNA, RNA and  proteins from  biological
samples such as blood or tissue. Assay technologies are used to  make
these isolated biomolecules visible. QIAGEN has developed and markets
more than  500  sample  and  assay  products  as  well  as  automated
solutions for such consumables. The Company provides its products  to
molecular    diagnostics    laboratories,    academic    researchers,
pharmaceutical  and  biotechnology  companies,  and  applied  testing
customers for purposes such as forensics, animal or food testing  and
pharmaceutical process control.  QIAGEN's assay technologies  include
one of the  broadest panels of  molecular diagnostic tests  available
worldwide. This panel includes the first FDA-approved test for  human
papillomavirus (HPV), the  primary cause of  cervical cancer.  QIAGEN
employs more  than  3,150  people in  over  30  locations  worldwide.
Further    information    about    QIAGEN    can    be    found    at


http://www.qiagen.com/.

Certain of  the statements  contained  in this  news release  may  be
considered forward-looking statements within  the meaning of  Section
27A of the U.S. Securities Act  of 1933, as amended, and Section  21E
of the  U.S. Securities  Exchange Act  of 1934,  as amended.  To  the
extent that  any  of  the statements  contained  herein  relating  to
QIAGEN's  products,  markets,  strategy  or  operating  results   are
forward-looking, such statements  are based  on current  expectations
that involve a number of uncertainties and risks. Such  uncertainties
and risks  include, but  are not  limited to,  risks associated  with
management of  growth  and international  operations  (including  the
effects  of  currency  fluctuations   and  risks  of  dependency   on
logistics),  variability   of  operating   results,  the   commercial
development of the applied testing markets, clinical research markets
and proteomics markets, women's  health/HPV testing markets,  nucleic
acid-based molecular diagnostics market, and genetic vaccination  and
gene  therapy   markets,  changing   relationships  with   customers,
suppliers and strategic  partners, competition,  rapid or  unexpected
changes in technologies, fluctuations in demand for QIAGEN's products
(including fluctuations due to general economic conditions, the level
and timing of  customers' funding, budgets,  and other factors),  our
ability to  obtain  regulatory  approval of  our  infectious  disease
panels, difficulties in  successfully adapting  QIAGEN's products  to
integrated solutions  and producing  such  products, the  ability  of
QIAGEN to identify and develop new products and to differentiate  its
products from competitors'  products, market  acceptance of  QIAGEN's
new  products  and  the  integration  of  acquired  technologies  and
businesses. In  addition certain  statements contained  in this  news
release are based on company assumptions, including, but not limited,
to revenue  allocations  based  on  business  segments.  For  further
information, refer  to the  discussions in  reports that  QIAGEN  has
filed with,  or  furnished  to,  the  U.S.  Securities  and  Exchange
Commission (SEC).



                             QIAGEN N.V.
             CONDENSED CONSOLIDATED STATEMENTS OF INCOME
                             (unaudited)


                                                 Three months
(in thousands, except per share data)            ended June 30,

                                                 2009         2008
Net sales                                      $   240,156  $ 217,888
  Cost of sales                                     80,656     69,812
Gross profit                                       159,500    148,076

Operating expenses:
  Research and development                          24,950     23,840
  Sales and marketing                               59,039     57,696
  General and administrative, integration and
other                                               24,618     29,713
  Acquisition related intangible amortization        4,011      2,816
Total operating expenses                           112,618    114,065

Income from operations                              46,882     34,011

Other income (expense):
  Interest income                                      678      2,324
  Interest expense                                 (7,302)    (9,187)
  Other income, net                                    778        424
Total other expense                                (5,846)    (6,439)

Income before provision for income taxes and
noncontrolling interest                             41,036     27,572
Provision for income taxes                          10,107      4,291
Net income                                          30,929     23,281
Less: Noncontrolling interest                            -         56
Net income attributable to QIAGEN N.V.         $    30,929  $  23,225

  Weighted average number of diluted common
shares                                             203,785    205,475

  Diluted net income attributable to QIAGEN
N.V. per common share                          $      0.15  $    0.11

  Diluted net income attributable to QIAGEN
N.V. per common
  share, adjusted                              $      0.24  $    0.20





                             QIAGEN N.V.
             CONDENSED CONSOLIDATED STATEMENTS OF INCOME
                             (unaudited)


                                                      Six months
(in thousands, except per share data)               ended June 30,

                                                      2009       2008
Net sales                                       $  461,089 $  424,994
  Cost of sales                                    155,140    135,694
Gross profit                                       305,949    289,300

Operating expenses:
  Research and development                          50,593     45,209
  Sales and marketing                              115,137    111,774
  General and administrative, integration and
other                                               48,406     58,802
  Acquisition related intangible amortization        7,902      6,466
Total operating expenses                           222,038    222,251

Income from operations                              83,911     67,049

Other income (expense):
  Interest income                                    1,863      5,296
  Interest expense                                (14,732)   (19,637)
  Other income, net                                  2,558      2,559
Total other expense                               (10,311)   (11,782)

Income before provision for income taxes and
noncontrolling interest                             73,600     55,267
Provision for income taxes                          17,987     11,592
Net income                                          55,613     43,675
Less: Noncontrolling interest                            -        116
Net income attributable to QIAGEN N.V.          $   55,613 $   43,559

  Weighted average number of diluted common
shares                                             203,476    205,300

  Diluted net income attributable to QIAGEN
N.V. per common share                           $     0.27 $     0.21

  Diluted net income attributable to QIAGEN
N.V. per common
  share, adjusted                               $     0.44 $     0.38





                             QIAGEN N.V.
                CONDENSED CONSOLIDATED BALANCE SHEETS



(in thousands, except par value)              June 30,   December 31,
                                                2009          2008
Assets                                       (unaudited)

Current Assets:
  Cash and cash equivalents                $     390,311  $   333,313
  Accounts receivable, net                       167,082      158,440
  Income taxes receivable                         15,436       14,441
  Inventories, net                               120,110      108,563
  Prepaid expenses and other                      63,167       61,424
  Deferred income taxes                           29,146       27,374
  Total current assets                           785,252      703,555

Long-Term Assets:
Property, plant and equipment, net               296,002      289,672
  Goodwill                                     1,169,617    1,152,105
  Intangible assets, net                         619,380      640,309
  Deferred income taxes                           76,328       73,766
  Other assets                                    23,948       25,916
     Total long-term assets                    2,185,275    2,181,768

Total assets                               $   2,970,527  $ 2,885,323

Liabilities and Shareholders' Equity

Current Liabilities:
  Accounts payable                         $      38,645  $    48,836
  Accrued and other liabilities                  165,640      163,513
  Income taxes payable                            23,409       14,288
  Current portion of long-term debt               25,000       25,000
  Current portion of capital lease
obligations                                        3,063        2,984
  Deferred income taxes                            8,696        7,754
     Total current liabilities                   264,453      262,375

Long-Term Liabilities:
  Long-term debt, net of current portion         920,000      920,000
  Capital lease obligations, net of
current portion                                   28,440       29,718
  Deferred income taxes                          211,405      212,589
  Other                                           11,615        6,797
     Total long-term liabilities               1,171,460    1,169,104

Shareholders' Equity:
  Common shares, EUR .01 par value:
     Authorized--410,000 shares
     Issued and outstanding--198,998
shares
       in 2009 and 197,839 shares in 2008          2,228        2,212
     Additional paid-in-capital                  974,492      958,665
     Retained earnings                           533,425      477,812
     Accumulated other comprehensive
income                                            24,469       15,155
       Total QIAGEN N.V. shareholders'
equity                                         1,534,614    1,453,844

     Total liabilities and shareholders'
equity                                     $   2,970,527  $ 2,885,323




                                     QIAGEN N.V.
                    RECONCILIATION OF REPORTED TO ADJUSTED FIGURES
                                     (unaudited)

                           Three months ended June 30, 2009
                           (in thousands, except EPS data)



                           Gross     Operating   Pre-tax Income Tax   Net      Diluted
              Net Sales   Profit      Income     Income              Income     EPS*

Reported
results        $ 240,156 $ 159,500 $    46,882 $  41,036 $ (10,107) $ 30,929 $    0.15

Adjustments:
 Business
integration,
acquisition
 related and
restructuring
costs                  -       281       4,939     4,939    (1,593)    3,346      0.02

 Purchased
intangibles
amortization           -    13,165      17,176    17,176    (5,983)   11,193      0.06

 Share-based
compensation           -       245       2,814     2,814      (866)    1,948      0.01
 Acquisition
related
write-off
of prepaid
expenses               -         -           -     1,132      (289)      843      0.00

 Total
adjustments            -    13,691      24,929    26,061    (8,731)   17,330      0.09

Adjusted
results        $ 240,156 $ 173,191 $    71,811 $  67,097 $ (18,838) $ 48,259 $    0.24


* Using
203,785
diluted shares

                           Three months ended June 30, 2008
                           (in thousands, except EPS data)


                           Gross     Operating   Pre-tax Income Tax   Net      Diluted
              Net Sales   Profit      Income     Income              Income     EPS*
Reported
results        $ 217,888 $ 148,076 $    34,011 $  27,572 $  (4,291) $ 23,225 $    0.11
Adjustments:
 Business
integration,
acquisition
 related and
restructuring
costs                  -         -       9,416     9,416    (3,356)    6,060      0.03

 Purchased
intangibles
amortization           -    11,949      14,765    14,765    (5,256)    9,509      0.05

 Share-based
compensation
                       -       305       2,363     2,363      (756)    1,607      0.01
 Total
adjustments
                       -    12,254      26,544    26,544    (9,368)   17,176      0.09
Adjusted
results        $ 217,888 $ 160,330 $    60,555 $  54,116 $ (13,659) $ 40,401 $    0.20


* Using 205,475 diluted shares




                                        QIAGEN N.V.
                       RECONCILIATION OF REPORTED TO ADJUSTED FIGURES
                                        (unaudited)


                               Six months ended June 30, 2009
                              (in thousands, except EPS data)


                                 Gross     Operating   Pre-tax              Net      Diluted
                    Net Sales   Profit      Income     Income  Income Tax  Income     EPS*

Reported results     $ 461,089 $ 305,949 $    83,911 $  73,600 $ (17,987) $ 55,613 $    0.27

Adjustments:
 Business
integration,
acquisition
 related and
restructuring costs          -       512       7,917     7,917    (2,480)    5,437      0.03

 Purchased
intangibles
 amortization                -    26,178      34,079    34,079   (11,891)   22,188      0.11

 Share-based
compensation                 -       454       5,003     5,003    (1,551)    3,452      0.02

 Acquisition related
write-off of
 prepaid expenses and
other
 asset impairment            -         -           -     2,703      (870)    1,833      0.01

 Total adjustments           -    27,144      46,999    49,702   (16,792)   32,910      0.17

Adjusted results     $ 461,089 $ 333,093 $   130,910 $ 123,302 $ (34,779) $ 88,523 $    0.44


* Using 203,476 diluted shares


                               Six months ended June 30, 2008
                              (in thousands, except EPS data)


                                 Gross     Operating   Pre-tax              Net      Diluted
                     Net Sales  Profit      Income     Income  Income Tax  Income     EPS*
Reported results     $ 424,994 $ 289,300 $    67,049 $  55,267 $ (11,592) $ 43,559 $    0.21
Adjustments:
 Business
integration,
 acquisition related
and
 restructuring costs         -         -      18,601    18,601    (6,622)   11,979      0.07
 Purchased
intangibles
 amortization                -    22,775      29,241    29,241   (10,430)   18,811      0.09
 Share-based
compensation                 -       540       4,541     4,541    (1,489)    3,052      0.01
 Total adjustments           -    23,315      52,383    52,383   (18,541)   33,842      0.17
Adjusted results     $ 424,994 $ 312,615 $   119,432 $ 107,650 $ (30,133) $ 77,401 $    0.38

* Using 205,300 diluted shares



Contacts:


Roland Sackers                Dr. Solveigh Mähler
Chief Financial Officer       Director Investor Relations
QIAGEN N.V.                   QIAGEN N.V.
e-mail:                       [phone]
[e-mail]     e-mail: [e-mail]

                              Albert F. Fleury
                              Associate Director Investor Relations
                              North America
                              QIAGEN N.V.
                              [phone]
                              e-mail: [e-mail]


 
--- End of Message ---

Qiagen N.V.
Spoorstraat 50 KJ Venlo Netherlands

WKN: 901626; ISIN: 
NL0000240000; Index: HDAX, MIDCAP, Prime All Share, TECH All Share, 
TecDAX;
Listed: Prime Standard in Frankfurter Wertpapierbörse, Freiverkehr in 
Börse Berlin, 
Freiverkehr in Börse Düsseldorf, Freiverkehr in Hanseatische 
Wertpapierbörse zu Hamburg, 
Freiverkehr in Niedersächsische Börse zu Hannover, Freiverkehr in 
Bayerische Börse München, 
Freiverkehr in Börse Stuttgart;